Guardant Health slides as FDA briefing raises questions tied to AstraZeneca camizestrant review

Guardant Health (GH) is down 6.1% today. Here is some analysis on what might have caused this price movement.

Analysis: The decline appears linked to newly public FDA advisory-committee materials that raise substantive questions about AstraZeneca’s camizestrant application and the SERENA-6 trial design, which relies on Guardant’s Guardant360 CDx to detect ESR1 mutations in circulating tumor DNA. Investors may be pricing in regulatory risk around whether the “early switch” strategy and the associated companion-diagnostic use will be viewed as clinically meaningful.

Details:

The FDA’s materials ahead of the April 30, 2026 Oncologic Drugs Advisory Committee meeting highlight uncertainty around whether switching treatment at ESR1-mutation detection (before radiographic progression) delivers durable patient benefit.

The briefing documents question the interpretability/clinical meaning of the progression-free survival approach used in SERENA-6 and note overall-survival data are immature, with a final analysis not anticipated until around 2028.

The FDA materials indicate the Guardant360 device is not currently approved for the specific ESR1-mutation detection use case as deployed in SERENA-6, and a PMA supplement for Guardant360 is under review alongside the camizestrant NDA.

Separately, traders may also be de-risking ahead of Guardant Health’s scheduled Q1 2026 earnings call on April 29, 2026, increasing near-term volatility.

Sources:

U.S. Food and Drug Administration, Guardant Health Investor Relations, Benzinga

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$GH Insider Trading Activity

$GH insiders have traded $GH stock on the open market 66 times in the past 6 months. Of those trades, 0 have been purchases and 66 have been sales.

Here’s a breakdown of recent trading of $GH stock by insiders over the last 6 months:

AMIRALI TALASAZ (Co-Chief Executive Officer) has made 0 purchases and 6 sales selling 100,000 shares for an estimated $10,505,473.
HELMY ELTOUKHY (Co-Chief Executive Officer) has made 0 purchases and 2 sales selling 90,565 shares for an estimated $9,402,220.
MICHAEL BRIAN BELL (Chief Financial Officer) has made 0 purchases and 13 sales selling 83,362 shares for an estimated $8,549,852.
TERILYN J. MONROE (Chief People Officer) has made 0 purchases and 14 sales selling 77,601 shares for an estimated $8,303,494.
KUMUD KALIA (Chief Information Officer) has made 0 purchases and 3 sales selling 42,000 shares for an estimated $4,021,864.
CHRIS FREEMAN (Chief Commercial Officer) has made 0 purchases and 11 sales selling 31,452 shares for an estimated $3,241,621.
IAN T CLARK has made 0 purchases and 3 sales selling 28,611 shares for an estimated $3,066,817.
DARYA CHUDOVA (Chief Technology Officer) has made 0 purchases and 3 sales selling 28,386 shares for an estimated $2,985,111.
JOHN G. SAIA (Chief Legal Officer) sold 8,996 shares for an estimated $865,865
MEDINA MANUEL HIDALGO has made 0 purchases and 6 sales selling 4,050 shares for an estimated $393,026.
MUSA TARIQ has made 0 purchases and 4 sales selling 696 shares for an estimated $63,429.

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API.

EARLY ACCESS

Receive GH Data Alerts

Real-time alerts on filings, insider trades, and market signals — before everyone else.

Get Alerts →

$GH Hedge Fund Activity

We have seen 278 institutional investors add shares of $GH stock to their portfolio, and 183 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC removed 7,131,895 shares (-78.8%) from their portfolio in Q4 2025, for an estimated $728,451,755
WELLINGTON MANAGEMENT GROUP LLP removed 2,842,566 shares (-87.5%) from their portfolio in Q4 2025, for an estimated $290,339,691
ALLIANCEBERNSTEIN L.P. added 1,761,785 shares (+1262.7%) to their portfolio in Q4 2025, for an estimated $179,948,719
FMR LLC added 1,572,168 shares (+190.7%) to their portfolio in Q4 2025, for an estimated $160,581,239
PRICE T ROWE ASSOCIATES INC /MD/ added 1,414,441 shares (+33.5%) to their portfolio in Q4 2025, for an estimated $144,471,003
POINT72 ASSET MANAGEMENT, L.P. added 1,396,754 shares (+1363.8%) to their portfolio in Q4 2025, for an estimated $142,664,453
DEEP TRACK CAPITAL, LP removed 1,354,086 shares (-32.6%) from their portfolio in Q4 2025, for an estimated $138,306,344

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API.

$GH Congressional Stock Trading

Members of Congress have traded $GH stock 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.

Here’s a breakdown of recent trading of $GH stock by members of Congress over the last 6 months:

SENATOR SHELDON WHITEHOUSE purchased up to $15,000 on 11/21.

To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard. You can access data on congressional stock trades through the Quiver Quantitative API.

$GH Analyst Ratings

Wall Street analysts have issued reports on $GH in the last several months. We have seen 3 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

BTIG issued a "Buy" rating on 02/20/2026
Canaccord Genuity issued a "Buy" rating on 12/22/2025
Mizuho issued a "Outperform" rating on 12/17/2025

To track analyst ratings and price targets for $GH, check out Quiver Quantitative's $GH forecast page.

$GH Price Targets

Multiple analysts have issued price targets for $GH recently. We have seen 15 analysts offer price targets for $GH in the last 6 months, with a median target of $130.0.

Here are some recent targets:

Luke Sergott from Barclays set a target price of $115.0 on 04/14/2026
Daniel Markowitz from Evercore ISI Group set a target price of $90.0 on 04/06/2026
David Westenberg from Piper Sandler set a target price of $130.0 on 02/24/2026
Mark Massaro from BTIG set a target price of $145.0 on 02/20/2026
Daniel Arias from Stifel set a target price of $130.0 on 02/20/2026
Brandon Couillard from Wells Fargo set a target price of $125.0 on 02/20/2026
Casey Woodring from JP Morgan set a target price of $130.0 on 02/20/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.